Evidence map›Paper›PMID 37286720›Full record

ArticleScientific reports2023

Association of systemic adverse reaction patterns with long-term dynamics of humoral and cellular immunity after coronavirus disease 2019 third vaccination.

Makoto Yoshida, Yurie Kobashi, Takeshi Kawamura, Yuzo Shimazu, Yoshitaka Nishikawa, Fumiya Omata, Hiroaki Saito, Chika Yamamoto, Tianchen Zhao, Morihiro Takita and 8 more

Abstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Makoto YoshidaFaculty of Medicine, Teikyo University School of Medicine, Itabashi-ku, Tokyo, 173-8605, Japan.
Yurie KobashiDepartment of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Fukushima, 960-1247, Japan.
Takeshi KawamuraIsotope Science Centre, The University of Tokyo, Bunkyo-ku, Tokyo, 113-0032, Japan.
Yuzo ShimazuDepartment of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Fukushima, 960-1247, Japan.
Yoshitaka NishikawaDepartment of Internal Medicine, Serireikai Group Hirata Central Hospital, Ishikawa Country, Fukushima, 963-8202, Japan.
Fumiya OmataDepartment of Internal Medicine, Serireikai Group Hirata Central Hospital, Ishikawa Country, Fukushima, 963-8202, Japan.
Hiroaki SaitoDepartment of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Fukushima, 960-1247, Japan.
Chika YamamotoDepartment of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Fukushima, 960-1247, Japan.
Tianchen ZhaoDepartment of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Fukushima, 960-1247, Japan.
Morihiro TakitaDepartment of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Fukushima, 960-1247, Japan.
Naomi ItoDepartment of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Fukushima, 960-1247, Japan.
Kenji TatsunoGenome Science & Medicine Laboratory, Research Center for Advanced Science and Technology (RCAST), The University of Tokyo, Meguro-ku, Tokyo, 153-8904, Japan.
Yudai KanekoLaboratory for Systems Biology and Medicine, Research Centre for Advanced Science and Technology (RCAST), The University of Tokyo, Meguro-ku, Tokyo, 153-8904, Japan.
Aya NakayamaIsotope Science Centre, The University of Tokyo, Bunkyo-ku, Tokyo, 113-0032, Japan.
Tatsuhiko KodamaLaboratory for Systems Biology and Medicine, Research Centre for Advanced Science and Technology (RCAST), The University of Tokyo, Meguro-ku, Tokyo, 153-8904, Japan.
Masatoshi WakuiDepartment of Laboratory Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, 160-8582, Japan.
Kenzo TakahashiTeikyo University Graduate School of Public Health, Itabashi-ku, Tokyo, 173-8605, Japan.
Masaharu TsubokuraDepartment of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Fukushima, 960-1247, Japan. tsubo-m@fmu.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of this study was to clarify the impact of adverse reactions on immune dynamics. We investigated the pattern of systemic adverse reactions after the second and third coronavirus disease 2019 (COVID-19) vaccinations and their relationship with immunoglobulin G against severe acute respiratory syndrome coronavirus 2 spike 1 protein titers, neutralizing antibody levels, peak cellular responses, and the rate of decrease after the third vaccination in a large-scale community-based cohort in Japan. Participants who received a third vaccination with BNT162b2 (Pfizer/BioNTech) or mRNA-1273 (Moderna), had two blood samples, had not had COVID-19, and had information on adverse reactions after the second and third vaccinations (n = 2198) were enrolled. We collected data on sex, age, adverse reactions, comorbidities, and daily medicine using a questionnaire survey. Participants with many systemic adverse reactions after the second and third vaccinations had significantly higher humoral and cellular immunity in the peak phase. Participants with multiple systemic adverse reactions after the third vaccination had small changes in the geometric values of humoral immunity and had the largest geometric mean of cellar immunity in the decay phase. Systemic adverse reactions after the third vaccination helped achieve high peak values and maintain humoral and cellular immunity. This information may help promote uptake of a third vaccination, even among those who hesitate due to adverse reactions.

Indexed as

BNT162 VaccineCOVID-19Antibodies, ViralComplementary TherapiesHumansImmunity, CellularImmunity, HumoralVaccinationAntibodies, ViralBNT162 Vaccine

Identifiers

PMID37286720
PMCPMC10246541

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.